Burden of Insomnia Among Individuals With Major Depressive Disorder: Cross-Sectional Observational Study
Belastung durch Insomnie bei Personen mit Major Depression: querschnittliche Beobachtungsstudie
Interactive Journal of Medical Research · 2026-09-21 · 15 · e93231-e93231
DOI: 10.2196/93231 ↗Auf einen Blick
Bei 1.250 Personen mit MDD und Insomnie-Symptomen war Insomnie häufig und belastend. Trotz hoher Medikamentennutzung blieben Schlafprobleme bestehen und beeinträchtigten den Alltag.
Fragestellung
Wie stark ist die Belastung durch Insomnie bei Personen mit MDD und Insomnie-Symptomen und welchen Einfluss hat sie auf wahrgenommene Krankheitslast und Lebensqualität?
Methode
Nichtinterventionelle, querschnittliche Online-Studie von Oktober 2022 bis Februar 2023 bei Erwachsenen mit selbstberichteter MDD und Insomnie-Symptomen in den USA oder 5 europäischen Ländern.
Ergebnisse
1.250 Teilnehmende; etwa 60 % berichteten moderate bis schwere Insomnie-Symptome. Rund die Hälfte hatte 8 bis 15 Insomnienächte in 2 Wochen; fast alle nannten negative Folgen für die tägliche Funktion.
Schlussfolgerung der Autor:innen
Insomnie-Symptome sind bei Patient:innen mit MDD häufig und belastend. Trotz hoher Medikamentennutzung sind sie unzureichend kontrolliert; integrierte Behandlungsstrategien für Stimmung und Schlaf sind erforderlich.
Kernaussagen
- Etwa 60 % berichteten moderate bis schwere Insomnie-Symptome.
- Trotz Antidepressiva und Schlafmedikation blieben Schlafprobleme bestehen.
- Die meisten nannten Einschränkungen von Alltag, Kognition und Produktivität.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Querschnittstudie in Interactive Journal of Medical Research, published online on 2026-09-21. Written by Josh Hamilton and 3 co-authors. Institution: The Hamilton Group Behavioral Health LLC, Las Vegas, NV, United States. 42 references. The full text is freely available in PubMed Central.
Topics: Schlaf
Abstract (original language)
Background
Insomnia is a common and persistent symptom in major depressive disorder (MDD), associated with poorer outcomes and reduced quality of life (QoL). Despite its prevalence, recent patient-reported data on the burden of insomnia symptoms in MDD remains limited.
Objective
This study aimed to assess the burden of insomnia among individuals with MDD experiencing insomnia symptoms (MDDIS) and its impact on patient-perceived disease burden and QoL.
Methods
A noninterventional, cross-sectional online study was conducted from October 2022 to February 2023 in adults with self-reported MDD and insomnia symptoms, residing in the United States or 1 of 5 European countries (EU5: France, Germany, Italy, Spain, and the United Kingdom). Participants completed validated questionnaires (Patient Health Questionnaire-9 [PHQ-9] for depression severity and Insomnia Severity Index [ISI] for insomnia severity) and provided data on demographics, clinical history, treatment experience, and perceptions. Descriptive statistics were used to summarize results, and subgroup analyses were conducted based on depression status and severity.
Results
Among 1250 participants (United States: 500; EU5: 750), most were cisgender women (United States: 363/500, 72%; EU5: 637/750, 85%), aged ~48 years, and on average 13.4 years in the United States and 11.2 years in EU5 had passed since being diagnosed with MDD. Around 60% (United States: 312/500; EU5: 439/750) reported having moderate to severe insomnia symptoms. Most had used antidepressants (United States: 460/500, 92%; EU5: 646/750, 86%) at least 40% (United States: 198/500; EU5: 343/750) in both regions reported using sleep-related medications (over-the-counter sleep aids, dual-purpose medication, or sleep-specific medication). However, insomnia symptoms persisted, with around half of participants reporting 8 to 15 insomnia nights over 2 weeks. Insomnia symptom severity differed significantly according to depression severity and current depressive episode status. Nearly all participants reported negative consequences for daily functioning, including irritability, cognitive impairment, and reduced productivity, and approximately two-thirds identified sleep disturbances as having a major impact on their daily lives. Satisfaction with current treatments, particularly their effectiveness on sleep, was low, and 65%‐71% (488/750-354/500) of participants expressed a desire for alternative therapies.
Conclusions
Insomnia symptoms are highly prevalent and burdensome among patients with MDD, severely affecting daily life and perceived treatment success. Insomnia remains inadequately controlled despite high medication use. These findings emphasize the need for integrated treatment strategies targeting both mood and sleep symptoms. Given its role in depression relapse, suicidality, and treatment resistance, addressing insomnia symptoms in MDD should be a clinical priority.
Subjects
Author keywords
Authors and institutions
- The Hamilton Group Behavioral Health LLC, Las Vegas, NV, United States.
- Carenity, 1 Rue de Stockholm, Paris, 75008, France.
- Janssen Cilag A/S, Birkerød, Denmark.
- Janssen Scientific Affairs, Titusville, NJ, United States.
Cite
APA
Hamilton, J., Pain, E., Riise, J., & Zhang, Z. (2026). Burden of Insomnia Among Individuals With Major Depressive Disorder: Cross-Sectional Observational Study. Interactive Journal of Medical Research, 15, e93231-e93231. https://doi.org/10.2196/93231
Vancouver
Hamilton J, Pain E, Riise J, Zhang Z. Burden of Insomnia Among Individuals With Major Depressive Disorder: Cross-Sectional Observational Study. Interactive Journal of Medical Research. 2026;15:e93231-e93231. doi:10.2196/93231
BibTeX
@article{Hamilton2026,
author = {Hamilton, Josh and Pain, Emilie and Riise, Jesper and Zhang, Zhiheng},
title = {Burden of Insomnia Among Individuals With Major Depressive Disorder: Cross-Sectional Observational Study},
journal = {Interactive Journal of Medical Research},
year = {2026},
volume = {15},
pages = {e93231--e93231},
doi = {10.2196/93231}
}
EUVIMED